Organisation paid for research Program year 2025 Source: CMS Open Payments

Arizona Neuroscience Research.LLC

Neither a doctor nor a teaching hospital

Research payments

$120,559

12 payments

Through program year 2025, Arizona Neuroscience Research.LLC is reported as receiving $120,559 in research payments, across 12 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $36,751 7
2023 Research $45,654 2
2022 Research $26,666 2
2021 Research $11,487 1

Breakdown

Who paid Research payments · program years 2021–2025
  1. F. Hoffmann-La Roche AG $72,320 4 payments
  2. Ares Trading SA $36,751 7 payments
  3. EMD Serono, Inc. $11,487 1 payment
Studies the money was for Research payments · program years 2021–2025
  1. Roll Over Protocol for 3 Ocr Pivotal Studies Opera I Opera II and Oratorio to Extend the Ole $72,320 4 payments
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis $28,500 4 payments
  3. A Phase III, Multicenter, Randomized, ParallelGroup, Double Blind, Double Dummy, ActiveControlled Study of Evobrutinib Compared withTeriflunomide, in Participants with RelapsingMultiple Sclerosis to Evaluate Efficacy and Safety $11,487 1 payment
  4. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis $3,351 1 payment
  5. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis $2,800 1 payment
  6. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis $2,100 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record